

POSTER PRESENTATION

Open Access

Dual targeting of the tumor and its associated vasculature using a single bispecific chimeric antigen receptor molecule

Tiara Byrd^{1*}, Kristen Fousek¹, Antonella Pignata¹, Amanda Wakefield¹, Zakaria Grada², Kevin Aviles-Padilla¹, Bradley S Fletcher³, Meenakshi Hegde¹, Brad St Croix⁴, Nabil Ahmed¹

From Society for Immunotherapy of Cancer 29th Annual Meeting National Harbor, MD, USA. 6-9 November 2014

Background

We have previously demonstrated the efficacy of HER2 specific chimeric antigen receptor (CAR) T cells in animal models of human cancer. While HER2 CAR T cells induced tumor regression, tumors recurred in a subset of animals. Lytic co-targeting of the tumor endothelium could represent a strategy that enhances tumor control. Tumor endothelium marker 8 (TEM8) is a recently described tumor endothelium-restricted antigen conserved in both mice and humans that represents an attractive antigen for vascular targeting [1].

Purpose

To test the advantage of co-targeting TEM8 in conjunction with HER2 using a T cell product expressing a novel TEM8/HER2 bispecific CAR molecule.

Methods

We designed, *in silico*, a single CAR molecule with both TEM8 and HER2-specific exodomains joined together in tandem (thus termed TanCAR). A retroviral construct encoding a TEM8 specific single chain variable fragment (scFv) from the mAb SB5, a Glycine/Serine linker and a HER2 specific scFv (mAb FRP5) exodomain, followed by a CD28 transmembrane domain, and a CD28.CD3-zeta signaling endodomain was transduced CD3/CD28-activated T cells with RD114-pseudotyped retroviral particles to generate TEM8/HER2 bispecific TanCAR T cells. CAR expression was confirmed by flow cytometry. Standard immunoassays were used to test the CAR T cell functionality.

Results

TEM8/HER2 TanCAR molecules were expressed on the surface of up to 90% of primary T cells. Staining specific for FRP5 and SB5 ensured the expression of the TanCAR molecule in its entirety. TanCAR T cells selectively recognized and killed TEM8 and HER2 positive targets distinctly, as evidenced by the release of the immunostimulatory cytokines interferon-gamma and interleukin-2 in vitro and standard 4 hour ⁵¹Cr release cytotoxicity assays. Cytokine release and killing were significantly enhanced when TanCAR T cells encountered both target antigens simultaneously. The kinetics of T cell activation followed a second order kinetic equation denoting a superadditive or synergistic effect upon recognition of a second antigen. Minimal activation or cytolytic activity occurred with target negative controls or with CAR null T cells.


Conclusion

Co-targeting the tumor and its vasculature using bispecific TanCAR T cells could enhance activation of these cells and potentially be used to improve tumor control with therapeutic application in cancer patients.

Authors' details

¹Baylor College of Medicine, Houston, TX, USA. ²Brown University, Providence, RI, USA. ³University of Florida, Gainesville, FL, USA. ⁴National Cancer Institute, Frederick, MD, USA.

Published: 6 November 2014





Reference

 Chaudhary A, Hilton MB, Seaman S, Haines DC, Stevenson S, Lemotte PK, Tschantz WR, Zhang XM, Saha S, Fleming T, St Croix B: TEM8/ANTXR1 blockade inhibits pathological angiogenesis and potentiates tumoricidal responses against multiple cancer types. Cancer Cell 2012, 21(2):212-26.

doi:10.1186/2051-1426-2-S3-P6

Cite this article as: Byrd *et al.*: Dual targeting of the tumor and its associated vasculature using a single bispecific chimeric antigen receptor molecule. *Journal for ImmunoTherapy of Cancer* 2014 **2**(Suppl 3):P6.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit

